Physician profile
Mark A Williams
NPI 1033114988
$1,908.29
in general payments reported to CMS, 2019-2025
20 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $136 · 2021: $244 · 2022: $251 · 2023: $177 · 2024: $192 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $459.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $376.24 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $233.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.18 | 2020-2025 | Jardiance |
| Abbvie INC. | $188.13 | 2023-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $100.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Stryker Corporation | $37.59 | 2025 | Scopis Ent, Audion Et Dilation System |
| Amgen INC. | $36.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.26 | 2019 | |
| Astellas Pharma US INC | $29.16 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $26.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.67 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $21.26 | 2019 | |
| Tactile Systems Technology INC | $19.64 | 2024 | Flexitouch Plus, Entre Plus |
| Genentech USA, INC. | $17.91 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.79 | 2019 | |
| Allergan, INC. | $17.42 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.50 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.